FDG PET/CT (Oncology, Whole Body)
PET+ ContrastWhole Body
Indications
- Staging/restaging of most solid malignancies and lymphoma
- Treatment response assessment
- Detection of recurrence; characterization of indeterminate lesions
- Radiation therapy planning
- Cancer of unknown primary
Patient prep
- Fast at least 4-6 hours (water only); no caloric intake during uptake
- Check blood glucose: should be <200 mg/dL (optimal <140-150); reschedule or manage if high
- Avoid strenuous exercise 24 h (muscle uptake)
- Keep patient warm and resting/quiet during uptake (reduce brown fat/muscle uptake)
- Diabetics: schedule appropriately, hold short-acting insulin per protocol
- Verify pregnancy/breastfeeding status
Contrast
AgentF-18 FDG (fluorodeoxyglucose)
RouteIV
Dose10-15 mCi (370-555 MBq); weight-based ~2.5-5.0 MBq/kg
TimingUptake 60 min (acceptable range 55-75 min); consistency critical for SUV
Technique
- Integrated PET/CT, skull base to mid-thigh (eyes-to-thighs); add limbs for melanoma/sarcoma
- Low-dose CT for attenuation correction and localization (+/- diagnostic CT with IV/oral contrast)
- Arms up if possible to reduce artifact; void before scan (urinary excretion)
- ~2-4 min per bed position
Series / Sequences
| # | Series / Sequence | Plane | Notes |
|---|---|---|---|
| 1 | Whole-body PET | Axial/multiplanar | Skull base to mid-thigh; SUV quantification |
| 2 | CT (low-dose or diagnostic) | Axial | Attenuation correction + anatomic localization |
Key points
- Strict glucose control and consistent ~60-min uptake essential for reliable SUV
- Keep patient warm/still to minimize brown fat and muscle uptake
- Physiologic uptake: brain, myocardium (variable), liver, GU tract, bowel, lymphoid tissue
- Hyperglycemia/recent insulin shifts FDG to muscle and lowers tumor conspicuity
- Inflammation/infection and post-treatment changes can cause false positives
References
• Delbeke D, Coleman RE, Guiberteau MJ, et al. Procedure Guideline for Tumor Imaging with 18F-FDG PET/CT 1.0. J Nucl Med. 2006;47(5):885–895. link
• Boellaard R, Delgado-Bolton R, Oyen WJG, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328–354. doi:10.1007/s00259-014-2961-x
• ACR-ACNM-SNMMI-SPR Practice Parameter for Performing FDG-PET/CT in Oncology. Revised 2021 (Resolution 20). link
• Radiopaedia: PET-CT indications link
• Boellaard R, Delgado-Bolton R, Oyen WJG, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328–354. doi:10.1007/s00259-014-2961-x
• ACR-ACNM-SNMMI-SPR Practice Parameter for Performing FDG-PET/CT in Oncology. Revised 2021 (Resolution 20). link
• Radiopaedia: PET-CT indications link
Source: Researched — verify against your institution
‹ PreviousLymphoscintigraphy / Sentinel Lymph Node Mapping (Tc-99m Sulfur Colloid)Next ›PSMA PET/CT (Ga-68 PSMA-11 / F-18 Piflufolastat)
Reference template — verify and adapt to your scanner, vendor and institution before clinical use. Not a substitute for clinical judgment.